BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 25006185)

  • 1. Nonsteroidal anti-inflammatory drugs and cardiovascular outcomes in women: results from the women's health initiative.
    Bavry AA; Thomas F; Allison M; Johnson KC; Howard BV; Hlatky M; Manson JE; Limacher MC
    Circ Cardiovasc Qual Outcomes; 2014 Jul; 7(4):603-10. PubMed ID: 25006185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative cardiovascular safety of nonsteroidal anti-inflammatory drugs in patients with hypertension: a population-based cohort study.
    Dong YH; Chang CH; Wu LC; Hwang JS; Toh S
    Br J Clin Pharmacol; 2018 May; 84(5):1045-1056. PubMed ID: 29468706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular events associated with the use of four nonselective NSAIDs (etodolac, nabumetone, ibuprofen, or naproxen) versus a cyclooxygenase-2 inhibitor (celecoxib): a population-based analysis in Taiwanese adults.
    Huang WF; Hsiao FY; Wen YW; Tsai YW
    Clin Ther; 2006 Nov; 28(11):1827-36. PubMed ID: 17213003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk.
    Motsko SP; Rascati KL; Busti AJ; Wilson JP; Barner JC; Lawson KA; Worchel J
    Drug Saf; 2006; 29(7):621-32. PubMed ID: 16808554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclooxygenase selectivity of nonsteroidal anti-inflammatory drugs and risk of stroke.
    Haag MD; Bos MJ; Hofman A; Koudstaal PJ; Breteler MM; Stricker BH
    Arch Intern Med; 2008 Jun; 168(11):1219-24. PubMed ID: 18541831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis.
    Becker MC; Wang TH; Wisniewski L; Wolski K; Libby P; Lüscher TF; Borer JS; Mascette AM; Husni ME; Solomon DH; Graham DY; Yeomans ND; Krum H; Ruschitzka F; Lincoff AM; Nissen SE;
    Am Heart J; 2009 Apr; 157(4):606-12. PubMed ID: 19332185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Harmful effects of NSAIDs among patients with hypertension and coronary artery disease.
    Bavry AA; Khaliq A; Gong Y; Handberg EM; Cooper-Dehoff RM; Pepine CJ
    Am J Med; 2011 Jul; 124(7):614-20. PubMed ID: 21596367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.
    Nissen SE; Yeomans ND; Solomon DH; Lüscher TF; Libby P; Husni ME; Graham DY; Borer JS; Wisniewski LM; Wolski KE; Wang Q; Menon V; Ruschitzka F; Gaffney M; Beckerman B; Berger MF; Bao W; Lincoff AM;
    N Engl J Med; 2016 Dec; 375(26):2519-29. PubMed ID: 27959716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current perspective on the cardiovascular effects of coxibs.
    Konstam MA; Weir MR
    Cleve Clin J Med; 2002; 69 Suppl 1():SI47-52. PubMed ID: 12086293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Aspirin Coadministration on the Safety of Celecoxib, Naproxen, or Ibuprofen.
    Reed GW; Abdallah MS; Shao M; Wolski K; Wisniewski L; Yeomans N; Lüscher TF; Borer JS; Graham DY; Husni ME; Solomon DH; Libby P; Menon V; Lincoff AM; Nissen SE
    J Am Coll Cardiol; 2018 Apr; 71(16):1741-1751. PubMed ID: 29673465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk.
    Solomon DH; Avorn J; Stürmer T; Glynn RJ; Mogun H; Schneeweiss S
    Arthritis Rheum; 2006 May; 54(5):1378-89. PubMed ID: 16645966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aspirin and other non-steroidal anti-inflammatory drugs for the prevention of dementia.
    Jordan F; Quinn TJ; McGuinness B; Passmore P; Kelly JP; Tudur Smith C; Murphy K; Devane D
    Cochrane Database Syst Rev; 2020 Apr; 4(4):CD011459. PubMed ID: 32352165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction.
    Kimmel SE; Berlin JA; Reilly M; Jaskowiak J; Kishel L; Chittams J; Strom BL
    Ann Intern Med; 2005 Feb; 142(3):157-64. PubMed ID: 15684203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiorenal risk of celecoxib compared with naproxen or ibuprofen in arthritis patients: insights from the PRECISION trial.
    Obeid S; Libby P; Husni E; Wang Q; Wisniewski LM; Davey DA; Wolski KE; Xia F; Bao W; Walker C; Ruschitzka F; Nissen SE; Lüscher TF
    Eur Heart J Cardiovasc Pharmacother; 2022 Sep; 8(6):611-621. PubMed ID: 35234840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular and Bleeding Risks Associated With Nonsteroidal Anti-Inflammatory Drugs After Myocardial Infarction.
    Kang DO; An H; Park GU; Yum Y; Park EJ; Park Y; Jang WY; Kim W; Choi JY; Roh SY; Na JO; Kim JW; Kim EJ; Rha SW; Park CG; Seo HS; Choi CU
    J Am Coll Cardiol; 2020 Aug; 76(5):518-529. PubMed ID: 32731930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone).
    Reicin AS; Shapiro D; Sperling RS; Barr E; Yu Q
    Am J Cardiol; 2002 Jan; 89(2):204-9. PubMed ID: 11792343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease.
    Ray WA; Varas-Lorenzo C; Chung CP; Castellsague J; Murray KT; Stein CM; Daugherty JR; Arbogast PG; García-Rodríguez LA
    Circ Cardiovasc Qual Outcomes; 2009 May; 2(3):155-63. PubMed ID: 20031832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction.
    Gislason GH; Jacobsen S; Rasmussen JN; Rasmussen S; Buch P; Friberg J; Schramm TK; Abildstrom SZ; Køber L; Madsen M; Torp-Pedersen C
    Circulation; 2006 Jun; 113(25):2906-13. PubMed ID: 16785336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cause-specific cardiovascular risk associated with nonsteroidal anti-inflammatory drugs among myocardial infarction patients--a nationwide study.
    Olsen AM; Fosbøl EL; Lindhardsen J; Andersson C; Folke F; Nielsen MB; Køber L; Hansen PR; Torp-Pedersen C; Gislason GH
    PLoS One; 2013; 8(1):e54309. PubMed ID: 23382889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of NSAID use with risk of bleeding and cardiovascular events in patients receiving antithrombotic therapy after myocardial infarction.
    Schjerning Olsen AM; Gislason GH; McGettigan P; Fosbøl E; Sørensen R; Hansen ML; Køber L; Torp-Pedersen C; Lamberts M
    JAMA; 2015 Feb; 313(8):805-14. PubMed ID: 25710657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.